Publications by authors named "Maryann Redlinger"

Claim this Profile
A
Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma.
Naomi B Haas, Leonard J Appleman, Mark Stein, Maryann Redlinger, Melissa Wilks

Clin Cancer Res· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.
Reshma Rangwala, Yunyoung C Chang, Janice Hu, Kenneth M Algazy, Tracey L Evans, Maryann Redlinger

Autophagy· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer.
Christine A Ciunci, Rodolfo F Perini, Anjali N Avadhani, Hyunseon C Kang, Weijing Sun, Maryann Redlinger

Cancer· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
Keith T Flaherty, Chetan Lathia, Reginald F Frye, Lynn Schuchter, Maryann Redlinger

Cancer Chemother Pharmacol· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.
Crystal S Denlinger, Rebecca Blanchard, Lu Xu, Coen Bernaards, Samuel Litwin, Maryann Redlinger

Cancer Chemother Pharmacol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of sorafenib in advanced thyroid cancer.
Vandana Gupta-Abramson, Andrea B Troxel, Anoma Nellore, Kanchan Puttaswamy, Maryann Redlinger

J Clin Oncol· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.
Keith T Flaherty, Joan Schiller, Lynn M Schuchter, Glenn Liu, David A Tuveson, Maryann Redlinger

Clin Cancer Res· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine.
Keith T Flaherty, James P Stevenson, Maryann Redlinger, Kenneth M Algazy, Bruce Giatonio

Cancer Chemother Pharmacol· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy.
Keith T Flaherty, James P Stevenson, Stephen M Hahn, Maryann Redlinger, Peter J O'Dwyer

Cancer Chemother Pharmacol· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer.
Weijing Sun, James P Stevenson, James M Gallo, Maryann Redlinger, Daniel Haller

Clin Cancer Res· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis